RxDoctor Payments Data

Heba Ferguson, MD

Family Medicine · Haysville, KSNPI 1881603421

Payments from drug & device makers

$9,758in general payments, 2019–2025

Across 644 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$966
  • AbbVie$618
  • Astellas Pharma US Inc$553
  • Amarin Pharma, Inc.$474
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,52998%
  • Education$2292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,758 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$221,962
Medicare patients
276
Services billed
13,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide294$316,952
JardianceEmpagliflozin226$201,612
FarxigaDapagliflozin Propanediol180$160,577
MounjaroTirzepatide54$68,429
TrulicityDulaglutide52$67,319
EliquisApixaban56$46,737
XareltoRivaroxaban28$28,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$28,440
Soliqua 100-33Insulin Glargine/Lixisenatide49$28,186
RybelsusSemaglutide18$23,808
Tresiba Flextouch U-200Insulin Degludec28$19,656
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$19,179
JanuviaSitagliptin Phosphate12$18,845
MyrbetriqMirabegron28$14,661
VascepaIcosapent Ethyl15$11,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$1,177$342,083324 claims
Boehringer IngelheimJardiance$376$201,612226 claims
AstraZenecaFarxiga$1,627$160,577180 claims
Lilly USA, LLCMounjaro, Trulicity$966$135,749106 claims
GSKTrelegy Ellipta, Anoro Ellipta$392$47,61961 claims
PfizerEliquis$228$46,73756 claims
Johnson & JohnsonXarelto$406$28,48228 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$260$28,18649 claims
MerckJanuvia$253$18,84512 claims
Astellas Pharma US IncMyrbetriq$553$14,66128 claims
Sumitomo Pharma America, Inc.Gemtesa$137$10,56216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Haysville

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →